A stock with a mixed support and controversial discussion can be a much better investment than a highly loved stock that gets promoted all over. For TRAB I am very optimistic on the longer term. I do not care much about the figures in the new 10-k since that represents only history under former management. With Dean and his team aboard I expect a new level for Therabiogen and the stock.
News 
Market Data 
Discover 
AI
